GHRP-2 Research: What 226 Studies Show (2026) | RetatrutideCompare

GHRP-2 — 226 studies indexed on PubMed. Synthetic ghrelin receptor agonist with appetite-stimulating activity in addition to GH release. Half-life: ~1 hour. FDA status: Approved Japan (diagnostic); not US-approved.

PubMed search-result count last fetched 2026-06-18. Records may include reviews, laboratory work, and animal studies; this is not a clinical trial count or a measure of efficacy.

Inspect the PubMed query and results

How many studies have been published on GHRP-2?

There are approximately 226 studies indexed on PubMed that mention GHRP-2 (Pralmorelin, KP-102), based on a search last updated 2026-06-18.

Is GHRP-2 FDA-approved?

FDA status: Approved Japan (diagnostic); not US-approved.

How does GHRP-2 work?

Synthetic ghrelin receptor agonist with appetite-stimulating activity in addition to GH release.

Reference facts

Also known as: Pralmorelin, KP-102
Category: Growth Hormone & Ghrelin
Mechanism of action: Synthetic ghrelin receptor agonist with appetite-stimulating activity in addition to GH release.
Targets: GHS-R1a
Indications under research or approved: Diagnostic GH stimulation test (approved Japan)
Regulatory status (reference entry): Approved Japan (diagnostic); not US-approved
Half-life: ~1 hour
Sequence notes: Hexapeptide H-D-Ala-D-2-MethylTrp-Ala-Trp-D-Phe-Lys-NH2.
Molecular weight (Da): 818
First reported: 1984

Primary References

Bowers et al., Endocrinology 1984 (GHRP)

Explore research articles about GHRP-2

This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.